ARIAD Announces Commercial Distribution Agreement for Iclusig (ponatinib) in Turkey
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
ARIAD Pharma (ARIA) Enters Distribution Agreement for Iclusig in Turkey
May 6, 2015 7:36 AM EDTARIAD Pharma (NASDAQ: ARIA) and Gen Ilac announced that ARIAD has granted Gen Ilac exclusive rights to distribute Iclusig® (ponatinib) in Turkey for patients with Philadelphia-positive leukemias.
Gen Ilac was granted the exclusive right to sell Iclusig as an investigational product in Turkey on a... More
